SAPPHIRE THERAPEUTICS INC has a total of 19 patent applications. Its first patent ever was published in 2005. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and Republic of Korea. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD, APOTEX TECHNOLOGIES INC and TONG WANG.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | Canada | 3 | |
#3 | Republic of Korea | 3 | |
#4 | China | 2 | |
#5 | Mexico | 2 | |
#6 | United States | 2 | |
#7 | EPO (European Patent Office) | 1 | |
#8 | Hong Kong | 1 | |
#9 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Polvino William J | 10 |
#2 | Lorimer Keith | 6 |
#3 | Pines Seemon H | 6 |
#4 | Littler Benjamin | 3 |
#5 | Paul Bernhard | 3 |
#6 | Carpi David B | 3 |
#7 | Smith Roy G | 3 |
#8 | Lou Yan-Ru | 2 |
#9 | Ahonen Merja | 2 |
#10 | Ylikomi Timo | 2 |
Publication | Filing date | Title |
---|---|---|
US2006074109A1 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | |
WO2006037023A2 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | |
US2006078494A1 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | |
EP1735055A1 | Method of reducing c-reactive protein using growth hormone secretagogues |